Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABD-006
- Development stage
- Preclinical
- Lead developer
- Abdera Therapeutics
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
ABD-006 is a radiolabeled antibody therapeutic candidate being developed as a precision radiopharmaceutical for the treatment of neoplasms (cancers). It is designed to deliver targeted radiation to tumor cells by binding to an undisclosed solid tumor antigen, leveraging Abdera Therapeutics' proprietary ROVEr platform. The drug is currently in preclinical development and has not yet entered clinical trials. Its mechanism of action involves the use of an antibody conjugated with a radioactive isotope, enabling selective delivery of cytotoxic radiation to cancer cells while sparing healthy tissue. The primary indication under investigation is neoplasms.
Beyond the preview
Go deeper on ABD-006.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABD-006.